Weinvestigated the efficacy of interferon-alpha (IFN-a) treatment in 5 patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM). Treatment with IFN-a yielded clinical improvement of gait, and sensory and/or sphincter disturbance in 4 out of the 5 HAMpatients. IFN-a treatment did not bring about uniform changes in lymphocyte subsets or anti-HTLV-I antibody titer of peripheral blood. Although the stimulation indexes to phytohemagglutinin, concanavalin A, and pokeweed mitogen were decreased in the culture of the peripheral blood lymphocytes (PBL) in the 5 HAMpatients before the treatment, the stimulation indexes to these mitogens were significantly increased except in 1 case after the IFN-a treatment. These changes were based primarily on the depression of the spontaneous proliferation of PBLwithout mitogen. These results appear to point out a very important phenomenon for the investigation of the pathogenesis of HAM.
Previously, we have reported that plasmapheresis is effective in treatment of patients with HAM(7). It is well knownthat with corticosteroid treatment HAMshow clinical improvement (1). Here, we investigated the effect of interferon-alpha (IFN-a ) treatment in patients with HAM. During the treatment, we studied the changes in immunological marker-lymphocyte subsets, anti-HTLV-I antibody, and the proliferative responses to several types of mitogens. Other tests
SUBJECTS AND METHODS

Su bjects
Measurement of anti-HTLV-I antibody in sera was performed using enzyme-linked immunosorbent assay (ELISA; using Eitest-ATL of Eisai, Inc.
Tokyo) (8) and Western blot analysis (9) using MT-2 cell lysate antigens (10). Determination of lymphocyte subsets of peripheral blood was carried out by a fluorescence-activated cell sorter (Spectrum III), using monoclonal antibodies (CD2, 3, 4, 8, 25,  OKIal and Leu 7, Ha).
RESULTS
The effect of IFN-a treatment
Treatment with IFN-a achieved clinical improvement in gait, and sensory and/or sphincter disturbance in 4 out of 5 HAMpatients (Table 2) 
